Cirrhosis News and Research RSS Feed - Cirrhosis News and Research

Cirrhosis is a condition in which the liver slowly deteriorates and malfunctions due to chronic injury. Scar tissue replaces healthy liver tissue, partially blocking the flow of blood through the liver. Scarring also impairs the liver’s ability to control infections, remove bacteria and toxins from the blood, process nutrients, hormones and drugs, make proteins that regulate blood clotting and produce bile to help absorb fats—including cholesterol—and fat-soluble vitamins.
Scientists discover promising approach to combat life-threatening bacterial infections without antibiotics

Scientists discover promising approach to combat life-threatening bacterial infections without antibiotics

Patients suffering from liver cirrhosis often die of life-threatening bacterial infections. In these patients the immune cells are unable to eliminate the bacterial infections. [More]
Researchers examine prevalence of CLD among ethnic minority populations in the U.S.

Researchers examine prevalence of CLD among ethnic minority populations in the U.S.

Chronic liver disease (CLD) and cirrhosis are serious liver conditions but little is known about how they affect ethnic minority populations in the United States. [More]
Health care resource use and costs of H.P. Acthar® gel for multiple sclerosis relapse

Health care resource use and costs of H.P. Acthar® gel for multiple sclerosis relapse

Mallinckrodt plc, a leading global specialty biopharmaceutical company, today announced new retrospective health economic data on H.P. Acthar® Gel (repository corticotropin injection; RCI), which may be an option for the management of multiple sclerosis (MS) relapses. [More]
FIB-4 index predicts HBV-related HCC

FIB-4 index predicts HBV-related HCC

Japanese researchers reveal an association between elevated FIB-4 index 24 weeks after the initiation of nucleos(t)ide analogue therapy and the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. [More]
Targeted molecular therapy reduces initial development of NAFLD in mice

Targeted molecular therapy reduces initial development of NAFLD in mice

Researchers report in the journal Cell Reports a targeted molecular therapy that dramatically reduces the initial development of Non Alcoholic Fatty Liver Disease (NAFLD) in laboratory mouse models of the disease. [More]
Researchers develop in vitro model system for investigating etiology of NAFLD

Researchers develop in vitro model system for investigating etiology of NAFLD

Researchers from the Institute for Stem Cell Research and Regenerative Medicine at the University Clinic of Düsseldorf have established an in vitro model system for investigating nonalcoholic fatty liver disease (NAFLD). [More]
Epclusa drug receives FDA approval for treating adult patients with chronic HCV

Epclusa drug receives FDA approval for treating adult patients with chronic HCV

The U.S. Food and Drug Administration approved Epclusa to treat adult patients with chronic hepatitis C virus (HCV) both with and without cirrhosis (advanced liver disease). [More]
Scientists discover link between two genes involved in PD and autoimmune diseases

Scientists discover link between two genes involved in PD and autoimmune diseases

A study publish in the journal CELL indicates that two genes associated with Parkinson's disease (PD) are key regulators of the immune system, providing direct evidence linking Parkinson's to autoimmune disease. [More]
HCC predictors identified for chronic HBV patients with newly diagnosed cirrhosis

HCC predictors identified for chronic HBV patients with newly diagnosed cirrhosis

In patients with chronic hepatitis B virus infection who have been newly diagnosed with cirrhosis, the risk of hepatocellular carcinoma development can be ascertained using several clinical and molecular factors, study findings indicate. [More]
Clinical trial finds pioglitazone drug safe and effective for NASH patients

Clinical trial finds pioglitazone drug safe and effective for NASH patients

Researchers have found that an existing diabetes drug can be used to halt progression of another disease that is a leading cause of liver transplants. [More]
New studies provide future treatment strategies for stomach ulcers, IBD and alcoholic liver disease

New studies provide future treatment strategies for stomach ulcers, IBD and alcoholic liver disease

Basic and translational research paves the way for breakthroughs that can ultimately change patient care. [More]
Portal vein hypertension diminishes after hepatitis C recovery

Portal vein hypertension diminishes after hepatitis C recovery

This inflammatory viral infection of the liver causes inflexible scar tissue to form. This in turn impedes blood flow through the organ, with resulting hypertension in the portal vein. [More]
New RNA aptamer can prevent pathogenic protein misfolding

New RNA aptamer can prevent pathogenic protein misfolding

Several diseases occur when mutations cause misfolding of proteins. These include "serpinopathies" which is a group of rare heritable diseases. They are caused by mutations of so-called "serpin" inhibitors of proteolytic enzymes involved in blood coagulation, tissue remodeling, and other important physiological functions. [More]

Novel enzyme immunoassay helps diagnose HCV infection in one simple step

The current standard in diagnosing Hepatitis C virus (HCV) infection requires two sequential steps that make it suboptimal, costly, inconvenient, time consuming, and globally not widely available or affordable. [More]
Scientists use new technique to repair fibrotic liver cells within the organ

Scientists use new technique to repair fibrotic liver cells within the organ

Advances in stem cell research have made it possible to convert patients' skin cells into heart cells, kidney cells, liver cells and more in the lab dish, giving researchers hope that one day such cells could replace organ transplantation for patients with organ failure. [More]
Ocaliva drug gets FDA approval for primary biliary cholangitis treatment

Ocaliva drug gets FDA approval for primary biliary cholangitis treatment

On Friday, May 27, the U.S. Food and Drug Administration granted accelerated approval for Ocaliva (obeticholic acid) for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as a single therapy in adults unable to tolerate UDCA. [More]
Portable breath sensor to detect lifestyle diseases? An interview with Osamu Tsuboi, Fujitsu Laboratories

Portable breath sensor to detect lifestyle diseases? An interview with Osamu Tsuboi, Fujitsu Laboratories

Generally, it is thought that there is a connection between concentrations of ammonia and liver disease, such as fatty liver and cirrhosis, Helicobacter pylori (H. pylori) infection, and kidney failure. [More]
Even light or non-drinkers who become easily inebriated may develop fatty liver disease

Even light or non-drinkers who become easily inebriated may develop fatty liver disease

People who have reduced enzyme activity to breakdown active aldehyde, i.e., those who become easily inebriated, are more likely to develop fatty liver disease even if they do not drink alcohol. [More]
Epigenetic modification of Igfbp2 gene may increase risk of obesity and fatty liver

Epigenetic modification of Igfbp2 gene may increase risk of obesity and fatty liver

Scientists of the German Center for Diabetes Research led by the German Institute of Human Nutrition have shown in a mouse model that the epigenetic modification of the Igfbp2 gene observed in the young animal precedes a fatty liver in the adult animal later in life. [More]
High levels of secretin hormone may play vital role in management of chronic liver diseases

High levels of secretin hormone may play vital role in management of chronic liver diseases

High levels of a digestive hormone called secretin may play an important role in the management of certain chronic liver diseases, according to new research published in the journal Hepatology. These findings could result in new ways to treat cholestatic liver diseases, a condition that impairs the movement of bile, the fluid produced by the liver to digest fats. [More]
Advertisement